Literature DB >> 1710253

Purification of anti-epithelial mucin monoclonal antibodies by epitope affinity chromatography.

M R Price1, M Sekowski, S J Tendler.   

Abstract

Monoclonal antibodies against the protein core of epithelial mucins have been found to react with the immunodominant sequence P D T R P A P (Burchell et al., 1989; Price et al., 1990a). Two immunoadsorbent matrices were prepared by linking the peptide A P D T R P A P G to CNBr-activated Sepharose and by linking the peptide C A P D T R P A P G to activated thiol-Sepharose, so that each immunoadsorbent contained the immunodominant motif. Anti-epithelial mucin antibodies (anti-breast carcinoma antibodies, anti-purified mucin antibodies and anti-human milk fat globule antibodies) were examined for reactivity with these preparations. The initial tests indicated that the substituted CNBr-activated Sepharose displayed lower non-specific antibody binding and this matrix was selected for further investigation. The anti-mucin antibodies were shown to react specifically with this affinity matrix and irrelevant antibodies failed to bind. A Sepharose-peptide immunoadsorbent column was examined for its capacity to purify several of these anti-mucin antibodies and it was determined that this procedure was highly efficient--purified IgG and IgM antibodies could be isolated from either hybridoma tissue culture supernatants or ascitic fluids. The capacity of the column was in excess of 40 mg antibody protein per ml of gel for the IgG3 antibody, C595 (anti-urinary mucin) and at least 10 mg antibody protein per ml of gel for the IgM antibody, NCRC-11 (anti-breast carcinoma). The procedure described permits the efficient purification of anti-mucin antibodies and provides a product which would be suitable for further investigations requiring highly immunoreactive antibodies (e.g., for radioimmunotherapy or immunoscintigraphy in patients with malignant disease).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710253     DOI: 10.1016/0022-1759(91)90354-i

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody.

Authors:  M E Verhoeyen; J A Saunders; M R Price; J D Marugg; S Briggs; E L Broderick; S J Eida; A T Mooren; R A Badley
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

Review 2.  Cancer-associated mucins: role in immune modulation and metastasis.

Authors:  Rakesh Bhatia; Shailendra K Gautam; Andrew Cannon; Christopher Thompson; Bradley R Hall; Abhijit Aithal; Kasturi Banerjee; Maneesh Jain; Joyce C Solheim; Sushil Kumar; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

3.  Evaluation of monoclonal idiotypic-specific antibodies as clearing antibodies for enhancement of target localisation by tumour-specific monoclonal antibodies: diversity of effects in nude mice with human tumour xenografts.

Authors:  M V Pimm; S J Gribben
Journal:  Eur J Nucl Med       Date:  1992

4.  Production and characterization of a recombinant anti-MUC1 scFv reactive with human carcinomas.

Authors:  G Denton; M Sekowski; D I Spencer; O D Hughes; A Murray; H Denley; S J Tendler; M R Price
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Influence of syngeneic monoclonal anti-idiotypic antibodies to murine monoclonal antibodies against tumour-associated antigens on the biodistribution of their target antibodies and their fragments.

Authors:  M V Pimm; S Demignot; S J Gribben
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice.

Authors:  M V Pimm; S J Gribben
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.